ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition
Item 8.01Results of Operations and Financial Condition.

Story continues below

On March15, 2018, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) provided a corporate update and announced its financial results for the fourth quarter ended December31, 2017 and its full-year financial results for the year ended December31, 2017. The press release is furnished as Exhibit99.1 to this report and is incorporated by reference herein.

Item 8.01. Other Events.

On March15, 2018, the Company issued a press release announcing partial responses in the first patients dosed with NY-ESO SPEAR T-cells in a second solid tumor indication: myxoid/round cell liposarcoma. The press release is furnished as Exhibit99.2 to this report and is incorporated by reference herein.

The information in Item 8.01 and Item 8.01 of this Form8-K (including the attached Exhibit99.1 and the attached Exhibit99.2) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 8.01 Financial Statements and Exhibits.

(d) Exhibits.




Press release regarding fourth quarter and full year 2017 financial results and business update dated March15, 2018


Press release announcing responses in second solid tumor indication with NY-ESO SPEAR T-cells dated March15, 2018

Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a18-8244_1ex99d1.htm EX-99.1 Exhibit 99.1     Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update   – Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T-cell therapies to treat solid tumors –   – Clinical momentum continues: dosing patients in MAGE-A4 “basket” study at 100 million cell dose level –   – Guidance confirmed: funded through to early 2020 –   – Conference call to be held today at 8:00 a.m. EDT (12:00 p.m. GMT) –   PHILADELPHIA,…
To view the full exhibit click here


Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

An ad to help with our costs